Randomised Intervention Treatment of Angina (RITA) data support coronary artery bypass graft (CABG) at one year
This article was originally published in Clinica
Executive Summary
Patients undergoing percutaneous transluminal coronary angioplasty (PTCA) for symptomatic multivessel coronary disease require significantly more reinterventions and are more likely to suffer angina than those undergoing coronary artery bypass graft (CABG). These are among the findings of the first-year results of CABRI, the Coronary Angioplasty versus Bypass Revascularisation Investigation (see Clinica No 569, p 17).
You may also be interested in...
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.